Comparing Revenue Performance: Takeda Pharmaceutical Company Limited or Sarepta Therapeutics, Inc.?

Takeda vs. Sarepta: A Decade of Revenue Growth

__timestampSarepta Therapeutics, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 201497570001777824000000
Thursday, January 1, 201512530001807378000000
Friday, January 1, 201654210001732051000000
Sunday, January 1, 20171545840001770531000000
Monday, January 1, 20183010340002097224000000
Tuesday, January 1, 20193808330003291188000000
Wednesday, January 1, 20205400990003197812000000
Friday, January 1, 20217018870003569006000000
Saturday, January 1, 20229330130004027478000000
Sunday, January 1, 202312433360004263762000000
Monday, January 1, 20244263762000000
Loading chart...

Cracking the code

A Tale of Two Pharmaceutical Giants: Revenue Trends from 2014 to 2023

In the competitive world of pharmaceuticals, revenue growth is a key indicator of success. This chart compares the revenue performance of Takeda Pharmaceutical Company Limited and Sarepta Therapeutics, Inc. over a decade, from 2014 to 2023. Takeda, a global leader, consistently outperformed with revenues peaking at approximately $4.26 trillion in 2023, marking a 140% increase from 2014. In contrast, Sarepta, a smaller player, showed impressive growth, with revenues surging by over 12,600% from 2014 to 2023, reaching around $1.24 billion. This stark contrast highlights the different scales and growth trajectories of these companies. While Takeda's revenue growth is steady, Sarepta's rapid rise underscores its potential in the biotech sector. Notably, data for 2024 is incomplete, leaving room for speculation on future trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025